MarketCap
Facebook
X
TelegramAnnual report 2024
added 03-26-2026
Orgenesis ROA Ratio 2011-2026 | ORGS
Annual ROA Ratio Orgenesis
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3565.14 | -380.44 | -16.37 | -30.17 | 1.43 | -26.08 | -24.24 | -31.02 | -27.46 | -11.51 | -244.74 | -4849.51 | -10376.7 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.43 | -10376.7 | -1506.3 |
Quarterly ROA Ratio Orgenesis
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -99.65 | -77.15 | -94.67 | -75.74 | -77.66 | -71.35 | -33.35 | -17.41 | -32.99 | -46.65 | -41.53 | -19.37 | -16.24 | 2.46 | 32.25 | -60.69 | -55.77 | -53.98 | -74.62 | 19.53 | 12.81 | 1.17 | -7.92 | -13.9 | -23.78 | -26.94 | -29.72 | -31.49 | -39.38 | -37.4 | -42.78 | -18.85 | -23.02 | -19.29 | -10.5 | -9.04 | -164.32 | -315.44 | -392.47 | -266.68 | -1087.41 | -1752.85 | -3035.83 | -3347.79 | -7241.03 | -10313.54 | -10766.91 | -16086.15 | -19178.11 | -18376.85 | -19652.59 | -9275.9 | -3091.97 | -3091.97 | -3091.97 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 32.25 | -19652.59 | -2395.35 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anavex Life Sciences Corp.
AVXL
|
-44.67 | $ 3.02 | 1.0 % | $ 258 M |  USA |
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
BioNTech SE
BNTX
|
65.02 | $ 90.9 | -0.31 % | $ 27.2 B | Germany |
 |
BioLineRx Ltd.
BLRX
|
-33.24 | $ 2.34 | 5.72 % | $ 908 M |  Israel |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Codexis
CDXS
|
-29.75 | $ 1.93 | 6.04 % | $ 168 M | USA |
 |
Cerus Corporation
CERS
|
-7.04 | $ 1.9 | 1.88 % | $ 362 M | USA |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | USA |
 |
Cullinan Management
CGEM
|
-49.04 | $ 15.2 | 5.34 % | $ 916 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Coherus BioSciences
CHRS
|
65.04 | $ 1.69 | -2.31 % | $ 198 M | USA |
 |
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-88.77 | $ 0.46 | -13.46 % | $ 5.27 M | Israel |
 |
Allena Pharmaceuticals
ALNA
|
-140.01 | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-20.15 | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-206.44 | - | 10.36 % | $ 9.8 M | USA |
 |
Aquestive Therapeutics
AQST
|
-52.23 | $ 4.11 | -0.48 % | $ 439 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-183.81 | $ 2.27 | 0.39 % | $ 1.01 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
19.41 | $ 24.91 | 0.89 % | $ 3.05 B | USA |
 |
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-24.26 | $ 8.3 | 3.36 % | $ 227 M | Israel |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-46.69 | $ 10.37 | 1.97 % | $ 138 M | USA |
 |
Cardiff Oncology
CRDF
|
-74.09 | $ 1.6 | 0.95 % | $ 107 M | USA |
 |
Curis
CRIS
|
-37.97 | $ 0.53 | -3.64 % | $ 6.98 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-41.32 | $ 38.09 | 2.31 % | $ 3.58 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-25.67 | $ 49.43 | -0.17 % | $ 4.44 B |  Schweiz |
 |
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
CytomX Therapeutics
CTMX
|
-11.46 | $ 4.41 | -3.4 % | $ 608 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
-33.8 | $ 0.87 | 1.26 % | $ 5.85 M | USA |
 |
Cue Biopharma
CUE
|
-63.02 | $ 0.17 | -7.12 % | $ 16.1 M | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
0.11 | - | - | $ 96.9 B | Britain |
 |
Celldex Therapeutics
CLDX
|
-44.38 | $ 31.43 | 1.18 % | $ 2.09 B | USA |
 |
Cyclerion Therapeutics
CYCN
|
-31.93 | $ 4.34 | -29.51 % | $ 10.9 M | USA |
 |
Avenue Therapeutics
ATXI
|
-99.25 | - | -52.27 % | $ 4.45 M | USA |